Histogen to Report Second Quarter 2021 Financial Results and Provide Business Update
Histogen Inc. (NASDAQ: HSTO) has announced the release date for its second-quarter financial results, which will be shared post-market on May 13, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Histogen Inc. (NASDAQ: HSTO) has announced the release date for its second-quarter financial results, which will be shared post-market on May 13, 2021. The company is focused on developing first-in-class restorative therapeutics utilizing its innovative technology platform and proprietary manufacturing process. Their therapies target various indications including hair growth and joint regeneration, enhancing biological function through hypoxia-induced multipotent cells.
Details
News Market Reaction – HSTO
The recorded move for HSTO in the trading session of this news was -0.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the second quarter will be released after the close of market on Thursday, May 13, 2021.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.